The LL2 cell line, also known as Lewis lung carcinoma (LLC) cells, is a mouse-derived cancer cell line established from a spontaneous lung tumor in a C57BL/6 mouse. It is a widely used experimental model for studying non-small cell lung cancer (NSCLC) and cancer metastasis in mice. The LL2 cell line is particularly useful for researchers because it can be implanted into immunocompetent mice, allowing for the study of tumor progression and immune responses in a more physiologically relevant context.

LL2 cells are often used to assess the efficacy of potential anti-cancer therapeutics, both in vitro and in vivo. They can be implanted subcutaneously or orthotopically (directly into the lung) in syngeneic mice, which enables the study of primary tumor growth, metastasis, and the effects of potential therapies on these processes.

These cells have been employed to investigate the roles of various signaling pathways, oncogenes, and tumor suppressor genes in the development and progression of lung cancer. Additionally, they have been used to study the tumor microenvironment, tumor angiogenesis, and the interactions between tumor cells and immune cells in the context of lung cancer.

In summary, the LL2 cell line is a valuable experimental model for lung cancer research, providing a valuable tool for studying the biology of the disease and the efficacy of potential therapeutic approaches.